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SignalingThe b-catenin-dependent Wnt signaling pathway has key roles in embryonic
development and adult tissues and is defective in various cancers. Recent
studies highlight the function of two transmembrane RING finger ubiquitin
ligases in modulating Wnt signaling and reveal roles for mutations in the RING
finger proteins in cancer.Eric R. Fearon1,2,3,5
and Jason R. Spence1,4
Cancers often harbor defects in
evolutionarily conserved pathways that
regulate embryonic development,
cell-fate specification and homeostasis
in adult tissues. The Wnt pathway is
a classic example of this phenomenon.
The cysteine-rich Wnt proteins are
roughly 40 kDa secreted molecules,
and Wnts function as close-range
signals for their context-specific
effects on varied cell phenotypes [1,2].
The actions of Wnts on target cells
include changes in gene expression,
cell polarization and directed migration
via engagement of distinct
downstream effector molecules [1]. For
the ‘canonical’ (b-catenin-dependent)
Wnt pathway, Wnts bind to a receptor
complex, composed of low-density
lipoprotein-related protein 5 or 6
(LRP5/6) and Frizzled (Fz). LRP5/6
have a single membrane-spanning
domain, and Fz proteins are
seven-transmembrane molecules.
There is a high level of complexity in
Wnt–Fz interactions, with 19 Wnt and
10 Fz molecules [2]. In the absence of
activating Wnt signals at the cell
surface, free b-catenin is bound to
the ‘destruction complex’, consisting
of glycogen synthase kinase (GSK) 3b,
Axin and adenomatous polyposis
coli (APC) tumor suppressor proteins,
and other factors. This complex
phosphorylates b-catenin in its
amino-terminal domain. The
phosphorylated b-catenin is
ubiquitinated, and then degraded by
the proteasome. Wnt-mediated
activation of the Fz–LRP5/6 complex
inhibits b-catenin degradation by
preventing b-catenin ubiquitination,
allowing newly synthesized b-catenin
protein to accumulate in the cell [2,3]
(Figure 1). In the nucleus, b-catenin can
bind to T cell factor (TCF) transcription
factors along with other proteins, and
the b-catenin–TCF complexes
modulate transcription of selectedgenes with roles in cell fate,
proliferation, and other processes [1,2].
Mutations in theb-catenin-dependent
Wnt signaling pathway contribute
especially to colorectal cancer. About
90% of colorectal cancers have
somatic mutations affecting certain
canonical Wnt pathway factors [4,5].
More than 50% of hepatocellular
carcinomas have mutations in the
canonical Wnt pathway [6], as do
significant subsets of other cancer
types [1,2,7]. Wnt pathway mutations
include inactivation of the APC protein
in most colorectal cancers [1,2,4,5]
or the AXIN1 protein in some
hepatocellular carcinomas [6], or
activating (oncogenic) mutations in key
phosphorylation sites in b-catenin’s
amino-terminal domain in
hepatocellular carcinomas and other
cancer types [1,2,7]. A major
consequence of the mutations is that
b-catenin is constitutively stabilized
in the absence of Wnt signals,
consequently altering the transcription
of b-catenin–TCF-regulated genes.
Several secreted and
transmembrane proteins modulate
Wnt-ligand signaling through the
Fz–LRP5/6 receptor. Inhibitors that
bind to Wnt ligands include secreted
Frizzled-related proteins (sFRPs) and
the secreted Wnt inhibitory factor 1
(WIF1) [2]. The Dickkopf (DKK) and
Sclerostin (SOST) secreted proteins
interfere with Wnt-simulated
Fz–LRP5/6 interactions, and the
APCDD1 (APC down-regulated 1)
transmembrane protein interferes with
Wnt binding to LRP5/6 [2]. Two distinct
protein families function through the
Fz–LRP5/6 complex to enhance Wnt
signaling. Norrin binds directly to
certain Fz proteins (such as Fz4) to
activate canonical Wnt signaling
independent of Wnts [2]. In contrast,
the four R-spondin proteins are
secreted, vertebrate-specific factors
that enhance signaling via Fz–LRP5/6
complexes, but only in the presence of
Wnt ligands [2].issue was how R-spondins enhanced
Wnt ligand-dependent signaling.
The first clues were provided by
demonstrations that R-spondins
bind to one of three leucine-rich,
G-protein-coupled receptors
(Lgr4/5/6) [8–10]. Lgr4/5/6 are
seven-transmembrane receptors with
similarity to the G-protein-coupled
hormone receptors, such as the
receptor for thyroid-stimulating
hormone [2,11]. Prior efforts had shown
Lgr5 gene expression was activated by
Wnt–b-catenin–TCF-dependent
signaling [2,11]. More significantly,
Lgr5 was a high fidelity biomarker of
Wnt-dependent crypt base columnar
intestinal stem cells in vivo, and single
intestinal Lgr5-expressing cells gave
rise to ‘organoids’ in vitro [12]. Lgr5 and
Lgr6 mark stem cells in other tissues
[11], whereas Lgr4 is more broadly
expressed and not likely to be stem cell
specific [11]. The finding that
R-spondins bind to Lgr familymembers
was obviously intriguing. However,
the mechanisms by which the
R-spondin–Lgr4/5/6 interactions might
enhance Wnt signaling through the
Fz–LRP5/6 co-receptor complex
remained unclear. Two recent papers in
Nature have now provided powerful
insights into how R-spondins likely
enhance Wnt signaling [13,14], and the
findings have important implications
for the cancer field.
Both papers took advantage of gene
expression profiling as a starting point.
Prior efforts had demonstrated that
multiple proteins encoded by genes
activated by b-catenin–TCF functioned
as negative feedback regulators of Wnt
signaling, including AXIN2, DKK1,
NKD1, APCDD1, and WIF1 [1,2]. Hao
et al. [13] sought to define genes whose
expression was tightly correlated with
AXIN2 expression and that might also
regulate the Wnt pathway. The
expression of genes encoding two
closely related transmembrane RING
(TM-RING) finger proteins with E3
ubiquitin ligase function, known as
ZNRF3 and RNF43, was linked to
b-catein function and largely paralleled
that of AXIN2, including in colorectal
cancers [13]. The same two genes drew
the attention of Koo et al. [14] in their
analysis of genes expressed in
Lgr5-expressing crypt base columnar
cells. The two papers diverge in terms
of the specific approaches and models
used to explore ZNRF3 and RNF43
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Figure 1. Model for Wnt reguation of the free pool of b-catenin.
Left: In the absence of an activating Wnt ligand, b-catenin is phosphorylated at multiple serine/
threonine residues in its amino-terminal domain by the ‘destruction complex’, consisting of
Axin, APC, GSK3b, and casein kinase 1a (CK1a). The amino-terminally phosphorylated
b-catenin is recognized by a ubiquitin ligation complex that contains bTrCP, and the ubiquiti-
nated b-catenin is degraded by the proteasome. The ubquitination and degradation of
b-catenin allows the destruction complex to bind and phosphorylate additional b-catenin
molecules. Right: In the presence of an activating Wnt ligand, which bridges the Fz–LRP5/6
proteins and brings about phosphorylation of cytoplasmic LRP5/6 sequences by CK1a, the
destruction complex is recruited to the phosphorylated cytoplasmic domain of LRP5/6. While
the destruction complex can still bind and phosphorylate b-catenin, ubiquitination by bTrCP is
blocked, allowing newly synthesized b-catenin to accumulate in the cell and activate transcrip-
tion in the nucleus, via interactions with TCF proteins and various co-factors, including the
p300/CBP histone acetyltransferases, BCL9, and Pygopus (Pygo), among others.
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at similar conclusions; namely, that
ZNRF3 andRNF43 regulate the stability
and levels of cell-surface Fz and
LRP5/6 proteins via ubiquitination
and then internalization and lysomal
degradation of the receptor
components. Both groups propose
that ZNRF3 andRNF43 function, akin to
AXIN2 and some other Wnt targets, as
negative feedback regulators of Wnt
signaling.
The paper from Hao et al. [13] also
provides data indicating that
R-spondins function to stabilize Wnt
receptor levels on the cell surface
through the interaction of an Lgr family
member and a ZNFR3/RNF43 member
with R-spondins. R-spondin binding tothis Lgr–TM-RING receptor complex
leads to the clearance of the TM-RING
protein from the membrane
(presumably via lysosomal degradation
of the complex), with resultant
increased levels of the Fz–LRP5/6
receptor complex and enhanced Wnt
signaling [13] (Figure 2). The paper from
Koo et al. [14] explores the roles of
RNF43 and ZNRF3 as presumptive
tumor suppressor proteins,
demonstrating that conditional
inactivation of both Rnf43 and Znrf3 in
murine intestinal epithelium led to
marked expansion of the proliferative
zone of the crypt and the formation
of epithelial tumors. The tumors
resembled intestinal adenomas and
were composed chiefly of cells foundat the base of normal intestinal crypts,
namely, crypt base columnar cells
(expressing Lgr5 and other stem-cell
markers) and Paneth cells [14]. Paneth
cells are a specialized cell type at the
crypt base in normal small intestine
that have a role in maintaining the
stem-cell niche by supplying Wnt
ligands and other signals to crypt base
columnar cells. Using intestinal
organoids generated from Rnf43/Znrf3
double-deficient epithelial cells, Koo
et al. [14] demonstrated that themutant
organoids no longer required
R-spondin1 supplementation, but were
highly dependent on locallly supplied
Wnts, such as Paneth-cell-derived
Wnt3a.
Hao et al. [13] noted that RNF43
inactivating mutations were found in
some pancreatic tumors [15,16], and
Koo et al. [14] noted that two colorectal
cancer cell lines with activating
b-catenin mutations (and not APC
inactivation) had inactivating RNF43
mutations [17]. In the HCT116
colorectal cancer cell line with
b-catenin and RNF43 defects, Koo
et al. [14] showed that RNF43
inactvation may allow Wnt ligands to
enhance b-catenin–TCF signaling
beyond that achieved by a b-catenin
mutation alone. RNF43 is inactivated in
various cancers, and in a recent study
10%of bile duct cancers were reported
to have RNF43 mutations [18]. Some
prior published results may also be
clarified by the findings in these Nature
papers. The Aaronson group had
previously reported thatb-catenin–TCF
signaling in the HCT116 colorectal
cancer cell line was dependent on Wnt
ligand [19], and their group recently
reported that LRP5/6 proteins are
overexpressed in some sarcomas in
the absence of demonstrable defects in
the genes encoding LRP5/6 [20].
Increased LRP5/6 protein levels in
these studies could be due in some
cases to inactivation of RNF43 and/or
ZNRF3.
Whether RNF43 and ZNRF3
negatively regulate all or nearly all
Fz–LRP5/6 co-receptor complexes or
only a subset is uncertain. The
identities of other proteins that might
be regulated by RNF43/ZNRF3 is also
unknown. Whether all R-spondin–Lgr
interactions can remove the TM-RING
complex from the cell surface remains
to be determined. Cell context and
variable expression patterns for RNF43
and ZNRF3 might offer some
explanation for why combined somatic
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Figure 2. Model for R-spondin (R-spo), Lgr4/5/6, and ZNRF3/RNF43 interactions in the modu-
lation of Wnt/b-catenin signaling.
Left: In the presence of Wnt ligand and the absence of R-spo, the transmembrane E3 ubiquitin
ligase proteins ZNRF3 or RNF43 (TM-RING) ubiquitinate Fz–LRP5/6 co-receptor proteins, re-
sulting in internalization and lysosomal degradation of the TM-RING–Fz–LRP complex. Right:
In the presence R-Spo, the TM-RING protein and Lgr proteins are brought into a complex by
R-spo, and the Lgr–R-spo–TM-RING complex is then targeted for lysosomal degradation in an
E3 ligase-dependent manner. This potentiates Wnt/b-catenin signaling by reducing Fz and
LRP turnover, thus allowing accumulation of Fz–LRP receptors at the cell surface.
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R851inactivation of Rnf43 and Znrf3 was
required to instigate intestinal
tumorigenesis in the mouse, yet only
the RNF43 gene seems to be
somatically mutated at moderate
frequency in human cancers. The basis
for why various other negative
feedback regulators of the Wnt
pathway, such as NKD1, DKK1, and
APCDD1, are not recurrently mutated
in cancer is not clear, though baseline
redundancy for some of their functions
in Wnt signaling may be part of the
answer. Data addressing some of these
issues will likely be forthcoming.
Moreover, given the potential
opportunities for targeting Wnt
signaling in cancers where RNF43
(and/or possibly ZNRF3) are defective,
there will likely be considerable
enthusiasm for new strategies and
reagents to target Wnt ligands andreceptors directly in certain subsets of
cancer.References
1. Klau, A., and Birchmeier, W. (2008). Wnt
signalling and its impact on development and
cancer. Nat. Rev. Cancer 8, 387–398.
2. Clevers, H., and Nusse, R. (2012). Wnt/
b-catenin signaling and disease. Cell 149,
1192–1205.
3. Li, V.S., Ng, S.S., Boersema, P.J., Low, T.Y.,
Karthaus, W.R., Gerlach, J.P., Mohammed, S.,
Heck, A.J., Maurice, M.M., Mahmoudi, T., et al.
(2012). Wnt signaling inhibits proteasomal
b-catenin degradation within a compositionally
intact Axin1 complex. Cell 149, 1245–1256.
4. Fearon, E.R. (2011). Molecular genetics of
colorectal cancer. Annu. Rev. Pathol. 6,
479–507.
5. The Cancer Genome Atlas (2012).
Comprehensive molecular characterization of
human colon and rectal cancer. Nature 487,
330–337.
6. Laurent-Puig, P., and Zucman-Rossi, J. (2006).
Genetics of hepatocellular tumors. Oncogene
25, 3778–3786.
7. Reya, T., and Clevers, H. (2005). Wnt
signalling in stem cells and cancer. Nature
434, 843–850.8. de Lau, W., Barker, N., Low, T.Y., Koo, B.K.,
Li, V.S., Teunissen, H., Kujala, P.,
Haegebarth, A., Peters, P.J., van de
Wetering, M., et al. (2011). Lgr5 homologues
associate with Wnt receptors and mediate
R-spondin signalling. Nature 476, 293–297.
9. Glinka, A., Dolde, C., Kirsch, N., Huang, Y.L.,
Kazanskaya, O., Ingelfinger, D., Boutros, M.,
Cruciat, C.M., and Niehrs, C. (2011). LGR4 and
LGR5 are R-spondin receptors mediating
Wnt/b-catenin and Wnt/PCP signalling. EMBO
Rep. 12, 1055–1061.
10. Carmon, K.S., Gong, X., Lin, Q., Thomas, A.,
and Liu, Q. (2011). R-spondins function
as ligands of the orphan receptors LGR4
and LGR5 to regulate Wnt/b-catenin signaling.
Proc. Natl. Acad. Sci. USA 108, 11452–11457.
11. Schuijers, J., and Clevers, H. (2012). Adult
mammalian stem cells: the role of Wnt, Lgr5
and R-spondins. EMBO J. 31, 2685–2696.
12. Sato, T., Vries, R.G., Snippert, H.J., van de
Wetering, M., Barker, N., Stange, D.E., van
Es, J.H., Abo, A., Kujala, P., Peters, P.J., et al.
(2009). Single Lgr5 stem cells build crypt-villus
structures in vivo without a mesenchymal
niche. Nature 459, 262–265.
13. Hao, H.X., Xie, Y., Zhang, Y., Charlat, O.,
Oster, E., Avello,M., Lei, H., Mickanin, C., Liu, D.,
Ruffner, H., et al. (2012). ZNRF3 promotes Wnt
receptor turnover in an R-spondin-sensitive
manner. Nature 485, 195–200.
14. Koo, B.K., Spit, M., Jordens, I., Low, T.Y.,
Stange, D.E., van de Wetering, M., van Es, J.H.,
Mohammed, S., Heck, A.J.R., Maurice, M.M.,
et al. (2012). Tumour suppressor RNF43 is
a stem cell E3 ligase that induces endocytosis
of Wnt receptors. Nature http://dx.doi.org/
10.1038/nature11308.
15. Wu, J., Jiao, Y., Dal Molin, M., Maitra, A., de
Wilde, R.F., Wood, L.D., Eshleman, J.R.,
Goggins, M.G., Wolfgang, C.L., Canto, M.I.,
et al. (2011). Whole-exosome sequencing of
neoplastic cysts of the pancreas reveals
recurrent mutations in components of the
ubiquitin-dependent pathways. Proc. Natl.
Acad. Sci. USA 108, 21188–21193.
16. Furukawa, T., Koboki, Y., Tanji, E., Yoshida, S.,
Hatori, T., Yamamoto, M., Shibata, N.,
Shimizu, K., Kamatani, N., and Shiratori, K.
(2011). Whole-exosome sequencing uncovers
frequent GNAS mutations in intraductal
papillary mucinous neoplasms of the pancreas.
Sci. Rep. 1, 161.
17. Ivanov, I., Lo, K.C., Hawthorn, L., Cowell, J.K.,
and Ionov, Y. (2007). Identifying candidate
colon cancer tumor suppressor genes using
inhibition of nonsense-mediated mRNA decay
in colon cancer cells. Oncogene 26, 2873–2884.
18. Ong, C.K., Subimerb, C., Pairojkul, C.,
Wongkham, S., Cutcutache, I., Yu, W.,
McPherson, J.R., Allen, G.E., Ng, C.C.,
Wong, B.H., et al. (2012). Exome sequencing
of liver fluke-associated cholangiocarcinoma.
Nat. Genet. 44, 690–693.
19. Bafico, A., Liu, G., Goldin, L., Harris, V., and
Aaronson, S.A. (2004). An autocrine mechanism
for constitutive Wnt pathway activation in
human cancer cells. Cancer Cell 6, 497–506.
20. Vijayakumar, S., Liu, G., Rus, I.A., Yao, S.,
Chen, Y., Akiri, G., Grumolato, L., and
Aaronson, S.A. (2011). High-frequency
canonical Wnt activation in multiple sarcoma
subtypes drives proliferation through a
TCF/b-catenin target gene CDC25A. Cancer
Cell 19, 601–612.
1Department of Internal Medicine,
2Department of Human Genetics,
3Department of Pathology, 4Department of
Cell and Developmental Biology,
5Department of the Cancer Center
University of Michigan Medical School,
Ann Arbor, MI 48109, USA.
E-mail: fearon@med.umich.eduhttp://dx.doi.org/10.1016/j.cub.2012.08.002
